Home » Catalyst Acquires Late-Stage Orphan Drug From BioMarin
Catalyst Acquires Late-Stage Orphan Drug From BioMarin
BioMarin Pharmaceutical has licensed North American rights to its EC-approved orphan drug Firdapse (amifampridine phosphate) to Catalyst Pharmaceutical Partners, and is making a $5 million investment in Catalyst to support the latter’s development of the drug in the U.S.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May